Immune Response BioPharma, Inc. Announces Fda Bla Fee Waiver Granted Clears Path for Remune Approval
Apr. 1, 2014 - NEW CITY, N.Y. -- Immune Response BioPharma, Inc. today, Announces the FDA has granted IRBP a SBA BLA Fee Waiver which clears a path for the REMUNE HIV/AIDS vaccine approval.
No comments:
Post a Comment